Clinical Study on the Detection of Mycoplasma Pneumonia Antibody and Hypersensitive C-reactive Proteinin Children
小儿肺炎支原体抗体与超敏C反应蛋白检验的临床探讨

摘要

目的 探讨临床制定小儿肺炎诊疗方案过程中肺炎支原体抗体与超敏C反应蛋白检验的应用价值。方法 随机抽取2021年3月至2022年3月间入我院进行诊治的小儿支原体肺炎患儿50例作为研究对象，并抽取50例健康体检儿童作为对照组，检验两组患儿肺炎支原体抗体及超敏C反应蛋白，以此来分析其临床应用价值。结果 通过检测发现观察组患儿的支原体抗体滴度比率超过1：40的整体占比达到了54%，而对照组的占比为2%，两组相比较观察组明显更高。且与对照组相比较，观察组患儿在肺炎支原体抗体、超敏C反应蛋白检测方面的阳性率明显超过对照组，差异显著，P<0.05。且与单独检验方式相比较，在患儿支原体肺炎灵敏度、阳性预测值和阴性预测值等指标方面肺炎支原体抗体与超敏C反应蛋白联合检验各指标值明显更高。差异显著，P<0.05。结论 在临床诊断小儿支原体肺炎的过程中肺炎支原体抗体和超敏C反应蛋白联合检验方式具有更好的应用效果和阳性率，值得临床大力推广。

Abstract

Objective To explore the value of detection of Mycoplasma pneumoniae antibody and hypersensitive C-reactive protein in the diagnosis and treatment of pediatric pneumonia.
Methods 50 children with mycoplasma pneumonia who were admitted to our hospital for treatment between March 2021 and March 2022 were randomly selected as the study object, and 50 healthy children were selected as the control group. The two groups of children were tested for mycoplasma pneumoniae antibody and hypersensitive C-reactive protein, so as to analyze their clinical application value.
Results It was found that 54% of the children in the observation group had Mycoplasma antibody titer ratio of more than 1:40, while 2% in the control group, which was significantly higher than that in the observation group. Compared with the control group, the positive rate of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein in the observation group was significantly higher than that in the control group (P<0.05). In addition, the combined test of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein was significantly higher in the sensitivity, positive predictive value, negative predictive value and other indicators of mycoplasma pneumoniae pneumonia in children compared with the single test. The difference was significant (P<0.05).
Conclusion   In the process of clinical diagnosis of mycoplasma pneumoniae pneumonia in children, the combined test of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein has better application effect and positive rate, which is worthy of being vigorously promoted in clinical practice.